Emergex Vaccines is a privately held company focusing on the development of medicines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen infected cells. Our vaccines illicit different responses than antibody producing vaccines which are associated with antibody dependent enhancement (ADE) complications.
We have developed the first approach to making set-point vaccines that modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, and thus preventing an acute or severe manifestation of the disease.
We work on addressing some of the world’s most immediate health threats including viral diseases such as Dengue Fever, Zika, Ebola, pandemic Flu, as well as serious intra-cellular bacterial infections.
Many of our vaccine candidates aim to address serious infectious diseases in less developed parts of the world, and making a positive social impact in these countries is an important part of Emergex’s mission.
We combine validated technologies with the latest scientific advances to develop our vaccines, including using synthetic peptide codes selected and determined through experiments on actual pathogen infected cells and using a proprietary quantum-sized nanocluster carrier system for delivery of these codes. Our technologies are advantageous in numerous ways.
Our business model is focused on developing vaccines that reduce morbidity and mortality against existing and newly emerging infectious outbreaks for use by governments (National Health Services), non-governmental organisations and the public.
Our activities have generated interest from governments, non-governmental organisations and charities who are interested in developing vaccines. These include:
- The Singapore Health Department, who will carry out preclinical and clinical studies on Dengue fever
- The Brazilian Health Department, who will carry out preclinical and clinical studies for Zika, Dengue and Yellow Fever
We have signed an agreement with the Institute of Molecular and Cell Biology (IMCB) to develop a vaccine for the highly contagious Hand, Foot & Mouth Disease. IMCB is a research institute in Singapore that is part of the government Agency for Science, Technology and Research (A*STAR).
We are forming partnerships with pharmaceutical companies to generate both milestone and future royalty revenue streams on retail sales of vaccines.
Watch our video on how we are pioneering a new approach to vaccine development and manufacturing.